Live feed08:00:00·27mPRReleasevia QuantisnowArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLCByQuantisnow·Wall Street's wire, on your screen.AVBP· ArriVent BioPharma Inc.Health Care
